Dry eye syndrome
|Dry eye syndrome|
|Other names||Dry eye, keratoconjunctivitis sicca, dry eye disease (DED), keratitis sicca|
|Diffuse lissamine green staining in a person with severe dry eye.|
|Symptoms||Dry eyes, irritation, redness, discharge, blurred vision|
|Causes||Contact lenses, meibomian gland dysfunction, pregnancy, Sjögren syndrome, vitamin A deficiency, LASIK surgery, antihistamines, hormone replacement therapy, antidepressants|
|Treatment||Artificial tears, wrap around glasses, changing certain medications|
|Medication||Ciclosporin, steroid eye drops|
Dry eye syndrome (DES), also known as keratoconjunctivitis sicca (KCS), is the condition of having dry eyes. Other associated symptoms include irritation, redness, discharge, and easily fatigued eyes. Blurred vision may also occur. Symptoms range from mild and occasional to severe and continuous. Scarring of the cornea may occur in untreated cases.
Dry eye occurs when either the eye does not produce enough tears or when the tears evaporate too quickly. This can result from contact lens use, meibomian gland dysfunction, pregnancy, Sjögren syndrome, vitamin A deficiency, omega-3 fatty acid deficiency, LASIK surgery, and certain medications such as antihistamines, some blood pressure medication, hormone replacement therapy, and antidepressants. Chronic conjunctivitis such as from tobacco smoke exposure or infection may also lead to the condition. Diagnosis is mostly based on the symptoms, though a number of other tests may be used.
Treatment depends on the underlying cause. Artificial tears are usually the first line of treatment. Wrap-around glasses that fit close to the face may decrease tear evaporation. Stopping or changing certain medications may help. The medication ciclosporin or steroid eye drops may be used in some cases. Another option is lacrimal plugs that prevent tears from draining from the surface of the eye. Dry eye syndrome occasionally makes wearing contact lenses impossible.
Dry eye syndrome is a common eye disease. It affects 5–34% of people to some degree depending on the population looked at. Among older people it affects up to 70%. In China it affects about 17% of people. The phrase "keratoconjunctivitis sicca" means "dryness of the cornea and conjunctiva" in the Latin language.
Signs and symptoms
Typical symptoms of dry eye syndrome are dryness, burning and a sandy-gritty eye irritation that gets worse as the day goes on. Symptoms may also be described as itchy, stinging or tired eyes. Other symptoms are pain, redness, a pulling sensation, and pressure behind the eye. There may be a feeling that something, such as a speck of dirt, is in the eye. The resultant damage to the eye's surface increases discomfort and sensitivity to bright light. Both eyes usually are affected.
There may also be a stringy discharge from the eyes. Although it may seem contradictory, dry eye can cause the eyes to water due to irritation. One may experience excessive tearing such as if something got into the eye. These reflex tears will not necessarily make the eyes feel better since they are the watery tears that are produced in response to injury, irritation, or emotion which lack the lubricating qualities necessary to prevent dry eye.
Because blinking coats the eye with tears, symptoms are worsened by activities in which the rate of blinking is reduced due to prolonged use of the eyes. These activities include prolonged reading, computer usage, driving, or watching television. Symptoms increase in windy, dusty or smoky (including cigarette smoke) areas, in dry environments high altitudes including airplanes, on days with low humidity, and in areas where an air conditioner (especially in a car), fan, heater, or even a hair dryer is being used. Symptoms reduce during cool, rainy, or foggy weather and in humid places, such as in the shower.
Most people who have dry eyes experience mild irritation with no long-term effects. However, if the condition is left untreated or becomes severe, it can produce complications that can cause eye damage, resulting in impaired vision or (rarely) in the loss of vision.
Symptom assessment is a key component of dry eye diagnosis – to the extent that many believe dry eye syndrome to be a symptom-based disease. Several questionnaires have been developed to determine a score that would allow for a diagnosis. The McMonnies & Ho dry eye questionnaire is often used in clinical studies of dry eyes.
Any abnormality of any one of the three layers of tears produces an unstable tear film, resulting in symptoms of dry eyes.
The most common cause of dry eye is increased evaporation of the tear film, typically as a result of Meibomian gland dysfunction. The meibomian glands are two sets of oil glands that line the upper and lower eyelids and secrete the oily outer layer of the tear film--the lipid layer. These glands often become clogged due to inflammation caused by blepharitis and/or rosacea, preventing an even distribution of oil. The result is an unstable lipid layer that leads to increased evaporation of the tear film.
In severe cases of MGD, the meibomiam glands can atrophy and cease producing oil entirely.
Decreased tear production
Keratoconjunctivitis sicca can be caused by inadequate tear production from lacrimal hyposecretion.  The aqueous tear layer is affected, resulting in aqueous tear deficiency (ATD). The lacrimal gland does not produce sufficient tears to keep the entire conjunctiva and cornea covered by a complete layer. This usually occurs in people who are otherwise healthy. Increased age is associated with decreased tearing. This is the most common type found in postmenopausal women.
In many cases, aqueous deficient dry eye may have no apparent cause (idiopathic). Other causes include congenital alacrima, xerophthalmia, lacrimal gland ablation, and sensory denervation. In rare cases, it may be a symptom of collagen vascular diseases, including relapsing polychondritis, rheumatoid arthritis, granulomatosis with polyangiitis, and systemic lupus erythematosus. Sjögren syndrome and other autoimmune diseases are associated with aqueous tear deficiency. Drugs such as isotretinoin, sedatives, diuretics, tricyclic antidepressants, antihypertensives, oral contraceptives, antihistamines, nasal decongestants, beta-blockers, phenothiazines, atropine, and pain relieving opiates such as morphine can cause or worsen this condition. Infiltration of the lacrimal glands by sarcoidosis or tumors, or postradiation fibrosis of the lacrimal glands can also cause this condition. Recent attention has been paid to the composition of tears in normal or dry eye individuals. Only a small fraction of the estimated 1543 proteins in tears are differentially deficient or upregulated in dry eye, one of which is lacritin. Topical lacritin promotes tearing in rabbit preclinical studies. Also, topical treatment of eyes of dry eye mice (Aire knockout mouse model of dry eye) restored tearing, and suppressed both corneal staining and the size of inflammatory foci in lacrimal glands.
Aging is one of the most common causes of dry eyes because tear production decreases with age. Several classes of medications (both prescription and OTC) have been hypothesized as a major cause of dry eye, especially in the elderly. Particularly, anticholinergic medications that also cause dry mouth are believed to promote dry eye. Dry eye may also be caused by thermal or chemical burns, or (in epidemic cases) by adenoviruses. A number of studies have found that diabetics are at increased risk for the disease.
About half of all people who wear contact lenses complain of dry eyes. There are two potential connections between contact usage and dry eye. Traditionally, it was believed that soft contact lenses, which float on the tear film that covers the cornea, absorb the tears in the eyes. The connection between a loss in nerve sensitivity and tear production is also the subject of current research.
Dry eye also occurs or becomes worse after LASIK and other refractive surgeries, in which the corneal nerves which stimulate tear secretion are cut during the creation of a corneal flap. Dry eye caused by these procedures usually resolves after several months, but it can be permanent. Persons who are thinking about refractive surgery should consider this.
An eye injury or other problem with the eyes or eyelids, such as bulging eyes or a drooping eyelid can cause keratoconjunctivitis sicca. Disorders of the eyelid can impair the complex blinking motion required to spread tears.
Abnormalities of the mucin tear layer caused by vitamin A deficiency, trachoma, diphtheric keratoconjunctivitis, mucocutaneous disorders and certain topical medications are also causes of keratoconjunctivitis sicca.
Persons with keratoconjunctivitis sicca have elevated levels of tear nerve growth factor (NGF). It is possible that this eye's surface NGF plays an important role in ocular surface inflammation associated with dry eyes.
Having dry eyes for a while can lead to tiny abrasions on the surface of the eyes. In advanced cases, the epithelium undergoes pathologic changes, namely squamous metaplasia and loss of goblet cells. Some severe cases result in thickening of the corneal surface, corneal erosion, punctate keratopathy, epithelial defects, corneal ulceration (sterile and infected), corneal neovascularization, corneal scarring, corneal thinning, and even corneal perforation.
Another contributing factor may be lacritin monomer deficiency. Lacritin monomer, active form of lacritin, is selectively decreased in aqueous deficient dry eye, Sjögren syndrome dry eye, contact lens-related dry eye and in blepharitis.
Some tests allow patients to be classified into one of two categories, “aqueous-deficient” or “hyperevaporative.” Diagnostic guidelines were published in 2007 by the Dry Eye Workshop. A slit lamp examination can be performed to diagnose dry eyes and to document any damage to the eye. When realizing this test, the practitioner is testing the eyelid margin.
A Schirmer's test can measure the amount of moisture bathing the eye. This test is useful for determining the severity of the condition. A five-minute Schirmer's test with and without anesthesia using a Whatman #41 filter paper 5 mm wide by 35 mm long is performed. For this test, wetting under 5 mm with or without anesthesia is considered diagnostic for dry eyes.
If the results for the Schirmer's test are abnormal, a Schirmer II test can be performed to measure reflex secretion. In this test, the nasal mucosa is irritated with a cotton-tipped applicator, after which tear production is measured with a Whatman #41 filter paper. For this test, wetting under 15 mm after five minutes is considered abnormal.
A lactoferrin analysis test provides good correlation with other tests.
The presence of the recently described molecule Ap4A, naturally occurring in tears, is abnormally high in different states of ocular dryness. This molecule can be quantified biochemically simply by taking a tear sample with a plain Schirmer test. Utilizing this technique it is possible to determine the concentrations of Ap4A in the tears of patients and in such way diagnose objectively if the samples are indicative of dry eye.
The tear osmolarity test has been proposed as a test for dry eye disease. Tear osmolarity may be a more sensitive method of diagnosing and grading the severity of dry eye compared to corneal and conjunctival staining, tear break-up time, Schirmer test, and meibomian gland grading. Others have recently questioned the utility of tear osmolarity in monitoring dry eye treatment.
Avoiding refractive surgery (LASIK & PRK), limiting contact lens use, limiting computer screen use, avoiding environmental conditions can decrease symptoms. Complications can be prevented by use of wetting and lubricating drops and ointments.
A variety of approaches can be taken to treatment. These can be summarised as: avoidance of exacerbating factors, tear stimulation and supplementation, increasing tear retention, and eyelid cleansing and treatment of eye inflammation.
Dry eyes can be exacerbated by smoky environments, dust and air conditioning and by our natural tendency to reduce our blink rate when concentrating. Purposefully blinking, especially during computer use and resting tired eyes are basic steps that can be taken to minimise discomfort. Rubbing one's eyes can irritate them further, so should be avoided. Conditions such as blepharitis can often co-exist and paying particular attention to cleaning the eyelids morning and night with mild soaps and warm compresses can improve both conditions.
Dry, drafty environments and those with smoke and dust should be avoided. This includes avoiding hair dryers, heaters, air conditioners or fans, especially when these devices are directed toward the eyes. Wearing glasses or directing gaze downward, for example, by lowering computer screens can be helpful to protect the eyes when aggravating environmental factors cannot be avoided. Using a humidifier, especially in the winter, can help by adding moisture to the dry indoor air.
For mild and moderate cases, supplemental lubrication is the most important part of treatment.
Application of artificial tears every few hours can provide temporary relief. Additional research is necessary to determine whether certain artificial tear formulations are superior to others in treating dry eye.
Autologous serum eye drops
A 2017 Cochrane review found mixed results when comparing autologous serum eye drops to artificial tears or saline. Evidence from the examined trials showed that autologous serum eye drops may have a small short-term benefit when compared to artificial tears, but there is no evidence of improvement after 2 weeks.
Lubricating tear ointments can be used during the day, but they generally are used at bedtime due to poor vision after application. They contain white petrolatum, mineral oil, and similar lubricants. They serve as a lubricant and an emollient. Application requires pulling down the lower eyelid and applying a small amount (0.25 in) inside. Depending on the severity of the condition, it may be applied from every hour to just at bedtime. It should never be used with contact lenses. Specially designed glasses that form a moisture chamber around the eye may be used to create additional humidity.
Inflammation occurring in response to tears film hypertonicity can be suppressed by mild topical steroids or with topical immunosuppressants such as ciclosporin (Restasis). Elevated levels of tear NGF can be decreased with 0.1% prednisolone.
Diquafosol, an agonist of the P2Y2 purinergic receptor, is approved in Japan for managing dry eye disease by promoting secretion of fluid and mucin from cells in the conjunctiva, rather than by directly stimulating the lacrimal glands.
Topical ciclosporin (topical ciclosporin A, tCSA) 0.05% ophthalmic emulsion is an immunosuppressant. The drug decreases surface inflammation. In a trial involving 1200 people, Restasis increased tear production in 15% of people, compared to 5% with placebo.
It should not be used while wearing contact lenses, during eye infections or in people with a history of herpes virus infections. Side effects include burning sensation (common), redness, discharge, watery eyes, eye pain, foreign body sensation, itching, stinging, and blurred vision. Long term use of ciclosporin at high doses is associated with an increased risk of cancer.
There are methods that allow both natural and artificial tears to stay longer.
In each eye, there are two puncta – little openings that drain tears into the tear ducts. There are methods to partially or completely close the tear ducts. This blocks the flow of tears into the nose, and thus more tears are available to the eyes. Drainage into either one or both puncta in each eye can be blocked.
Punctal plugs are inserted into the puncta to block tear drainage. It is not clear if punctal plugs are effective at reducing dry eye syndrome symptoms. Punctal plugs are thought to be "relatively safe", however, their use may result in epiphora (watery eyes), and more rarely, serious infection and swelling of the tear sac where the tears drain. They are reserved for people with moderate or severe dry eye when other medical treatment has not been adequate.
If punctal plugs are effective, thermal or electric cauterization of puncti can be performed. In thermal cauterization, a local anesthetic is used, and then a hot wire is applied. This shrinks the drainage area tissues and causes scarring, which closes the tear duct.
Heating systems that try to unblock the oil glands in the eye has some preliminary evidence of benefit.
In severe cases of dry eyes, tarsorrhaphy may be performed where the eyelids are partially sewn together. This reduces the palpebral fissure (eyelid separation), ideally leading to a reduction in tear evaporation.
Keratoconjunctivitis sicca usually is a chronic problem. Its prognosis shows considerable variance, depending upon the severity of the condition. Most people have mild-to-moderate cases, and can be treated symptomatically with lubricants. This provides an adequate relief of symptoms.
When dry eyes symptoms are severe, they can interfere with quality of life. People sometimes feel their vision blurs with use, or severe irritation to the point that they have trouble keeping their eyes open or they may not be able to work or drive.
Keratoconjunctivitis sicca is relatively common within the United States, especially so in older patients. Specifically, the persons most likely to be affected by dry eyes are those aged 40 or older. 10–20% of adults experience Keratoconjunctivitis sicca. Approximately 1 to 4 million adults (age 65–84) in the USA are affected.
While persons with autoimmune diseases have a high likelihood of having dry eyes, most persons with dry eyes do not have an autoimmune disease. Instances of Sjögren syndrome and keratoconjunctivitis sicca associated with it are present much more commonly in women, with a ratio of 9:1. In addition, milder forms of keratoconjunctivitis sicca also are more common in women. This is partly because hormonal changes, such as those that occur in pregnancy, menstruation, and menopause, can decrease tear production.
In areas of the world where malnutrition is common, vitamin A deficiency is a common cause. This is rare in the United States.
Racial predilections do not exist for this disease.
Other names for dry eye include dry eye syndrome, keratoconjunctivitis sicca (KCS), dysfunctional tear syndrome, lacrimal keratoconjunctivitis, evaporative tear deficiency, aqueous tear deficiency, and LASIK-induced neurotrophic epitheliopathy (LNE).
Among other animals, dry eye can occur in dogs, cats, and horses.
Keratoconjunctivitis sicca is common in dogs. Most cases are caused by a genetic predisposition, but chronic conjunctivitis, canine distemper, and drugs such as sulfasalazine and trimethoprim-sulfonamide also cause the disease. Symptoms include eye redness, a yellow or greenish discharge, corneal ulceration, pigmented cornea, and blood vessels on the cornea. Diagnosis is made by measuring tear production with a Schirmer tear test. Less than 15 milliliters of tears produced in a minute is abnormal.
Tear replacers are a mainstay of treatment, preferably containing methylcellulose or carboxymethyl cellulose. Ciclosporin stimulates tear production and acts as a suppressant on the immune-mediated processes that cause the disease. Topical antibiotics and corticosteroids are sometimes used to treat secondary infections and inflammation. A surgery known as parotid duct transposition is used in some extreme cases where medical treatment has not helped. This redirects the duct from the parotid salivary gland to the eye. Saliva replaces the tears. Dogs suffering from cherry eye should have the condition corrected to help prevent this disease.
Breeds with a higher risk of dry eye compared to other breeds include:
- American Cocker Spaniel
- Boston Terrier
- English Bulldog
- Cavalier King Charles Spaniel
- Lhasa Apso
- Miniature Schnauzer
- Shih Tzu
- West Highland White Terrier
Keratoconjunctivitis sicca is uncommon in cats. Most cases seem to be caused by chronic conjunctivitis, especially secondary to feline herpesvirus. Diagnosis, symptoms, and treatment are similar to those for dogs.
- Critser, Brice. "Lissamine green staining in keratoconjunctivitis sicca". Eye Rounds. The University of Iowa. Archived from the original on 7 August 2016. Retrieved 29 July 2016.
- "Facts About Dry Eye". NEI. February 2013. Archived from the original on 28 July 2016. Retrieved 29 July 2016.
- Kanellopoulos, AJ; Asimellis, G (2016). "In pursuit of objective dry eye screening clinical techniques". Eye and Vision. London. 3: 1. doi:10.1186/s40662-015-0032-4. PMC 4716631. PMID 26783543.
- Michelle Meadows (May–June 2005). "Dealing with Dry Eye". FDA Consumer Magazine. U.S. Food and Drug Administration. Archived from the original on February 23, 2008.
- Messmer, EM (30 January 2015). "The pathophysiology, diagnosis, and treatment of dry eye disease". Deutsches Ärzteblatt International. 112 (5): 71–81, quiz 82. doi:10.3238/arztebl.2015.0071. PMC 4335585. PMID 25686388.
- Tavares Fde, P; Fernandes, RS; Bernardes, TF; Bonfioli, AA; Soares, EJ (May 2010). "Dry eye disease". Seminars in Ophthalmology. 25 (3): 84–93. doi:10.3109/08820538.2010.488568. PMID 20590418. S2CID 207474207.
- Ding, J; Sullivan, DA (July 2012). "Aging and dry eye disease". Experimental Gerontology. 47 (7): 483–90. doi:10.1016/j.exger.2012.03.020. PMC 3368077. PMID 22569356.
- Liu, NN; Liu, L; Li, J; Sun, YZ (2014). "Prevalence of and risk factors for dry eye symptom in mainland china: a systematic review and meta-analysis". Journal of Ophthalmology. 2014: 748654. doi:10.1155/2014/748654. PMC 4216702. PMID 25386359.
- Firestein, Gary S. (2013). Kelley's textbook of rheumatology (9th ed.). Philadelphia: Elsevier/Saunders. p. 1179. ISBN 978-1437717389. Archived from the original on 2017-09-08.
- "Keratoconjunctivitis Sicca". The Merck Manual, Home Edition. Merck & Co. 2003-02-01. Archived from the original on 2006-11-12. Retrieved 2006-11-12.
- "Keratoconjunctivitis, Sicca". eMedicine. WebMD, Inc. January 27, 2010. Archived from the original on March 7, 2010. Retrieved September 3, 2010.
- "Dry eyes". MedlinePlus Medical Encyclopedia. U.S. National Library of Medicine. 2006-10-04. Archived from the original on 2006-12-06. Retrieved 2006-11-16.
- "Dry eyes". Mayo Clinic. Mayo Foundation for Medical Education and Research. 2006-06-14. Archived from the original on 2007-03-24. Retrieved 2006-11-17.
- Guo, Y; Peng, R; Feng, K; Hong, J (2016). "Diagnostic performance of McMonnies Questionnaire as a screening survey for dry eye: A multicenter analysis". Journal of Ophthalmology. 2016: 6210853. doi:10.1155/2016/6210853. PMC 4884592. PMID 27293876.
- Sendecka M, Baryluk A, Polz-Dacewicz M (2004). "Częstość występowania zespołu suchego oka" [Prevalence and risk factors of dry eye syndrome]. Przegla̧d Epidemiologiczny (in Polish). 58 (1): 227–33. PMID 15218664. Archived from the original on 2016-02-22.
- Puéchal, X; Terrier, B; Mouthon, L; Costedoat-Chalumeau, N; Guillevin, L; Le Jeunne, C (March 2014). "Relapsing polychondritis". Joint, Bone, Spine : Revue du Rhumatisme. 81 (2): 118–24. doi:10.1016/j.jbspin.2014.01.001. PMID 24556284.
- Cantarini, L; Vitale, A; Brizi, MG; Caso, F; Frediani, B; Punzi, L; Galeazzi, M; Rigante, D (February–March 2014). "Diagnosis and classification of relapsing polychondritis". Journal of Autoimmunity. 48–49: 53–59. doi:10.1016/j.jaut.2014.01.026. PMID 24461536.
- Zhou L, Zhao SZ, Koh SK, et al. (July 2012). "In-depth analysis of the human tear proteome". Journal of Proteomics. 75 (13): 3877–85. doi:10.1016/j.jprot.2012.04.053. PMID 22634083.
- Karnati R, Laurie DE, Laurie GW (December 2013). "Lacritin and the tear proteome as natural replacement therapy for dry eye". Experimental Eye Research. 117: 39–52. doi:10.1016/j.exer.2013.05.020. PMC 3844047. PMID 23769845.
- Samudre S, Lattanzio FA, Lossen V, et al. (August 2011). "Lacritin, a novel human tear glycoprotein, promotes sustained basal tearing and is well tolerated". Investigative Ophthalmology & Visual Science. 52 (9): 6265–70. doi:10.1167/iovs.10-6220. PMC 3176019. PMID 21087963.
- Vijmasi T, Chen FY, Balasubbu S, Gallup M, McKown RL, Laurie GW, McNamara NA (July 2014). "Topical administration of lacritin is a novel therapy for aqueous-deficient dry eye disease". Invest Ophthalmol Vis Sci. 55 (8): 5401–09. doi:10.1167/iovs.14-13924. PMC 4148924. PMID 25034600.
- Fraunfelder FT, Sciubba JJ, Mathers WD (2012). "The role of medications in causing dry eye". Journal of Ophthalmology. 2012: 285851. doi:10.1155/2012/285851. PMC 3459228. PMID 23050121.
- Kaiserman I, Kaiserman N, Nakar S, Vinker S (March 2005). "Dry eye in diabetic patients". American Journal of Ophthalmology. 139 (3): 498–503. doi:10.1016/j.ajo.2004.10.022. PMID 15767060.
- Mathers WD, Scerra C (2000). "Dry eye; investigators look at syndrome with new model". Ophthalmol Times. 25 (7): 1–3.
- Messmer, Elisabeth M. (2015). "The pathophysiology, diagnosis, and treatment of dry eye disease". Dtsch Arztebl Int. 112 (5): 71–81. doi:10.3238/arztebl.2015.0071. PMC 4335585. PMID 25686388.
- Peral A, Carracedo G, Acosta MC, Gallar J, Pintor J (September 2006). "Increased levels of diadenosine polyphosphates in dry eye". Investigative Ophthalmology & Visual Science. 47 (9): 4053–58. doi:10.1167/iovs.05-0980. PMID 16936123.
- Tomlinson, A. (April 2007). "2007 Report of the International Dry Eye WorkShop (DEWS)" (PDF). The Ocular Surface. 5 (2). Archived (PDF) from the original on 2012-02-27.
- "American Academy of Ophthalmology Cornea/External Disease Panel". October 2011. Archived from the original on 2012-03-09. Cite journal requires
- "10 Symptoms of Dry Eye Syndrome + Possible Causes". All About Vision. Retrieved 2018-04-04.
- "Dry eyes syndrome". MedlinePlus Medical Encyclopedia. U.S. National Library of Medicine. 2006-10-04. Archived from the original on 2006-11-19. Retrieved 2006-11-16.
- Lemp M.A. (2008). "Management of Dry Eye". American Journal of Managed Care. 14 (4): S88–S101. PMID 18452372. Archived from the original on 2012-06-05. Retrieved 2008-07-25.
- Pucker AD, Ng SM, Nichols JJ (2016). "Over the counter (OTC) artificial tear drops for dry eye syndrome". Cochrane Database Syst Rev. 2: CD009729. doi:10.1002/14651858.CD009729.pub2. PMC 5045033. PMID 26905373.
- Pan, Qing; Angelina, Adla; Marrone, Michael; Stark, Walter J.; Akpek, Esen K. (2017). "Autologous serum eye drops for dry eye". The Cochrane Database of Systematic Reviews. 2: CD009327. doi:10.1002/14651858.CD009327.pub3. ISSN 1469-493X. PMC 5510593. PMID 28245347.
- Tatlipinar S, Akpek E (2005). "Topical cyclosporine in the treatment of ocular surface disorders". Br J Ophthalmol. 89 (10): 1363–67. doi:10.1136/bjo.2005.070888. PMC 1772855. PMID 16170133.
- Barber L, Pflugfelder S, Tauber J, Foulks G (2005). "Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years". Ophthalmology. 112 (10): 1790–94. doi:10.1016/j.ophtha.2005.05.013. PMID 16102833.
- Koh, Shizuka (May 2015). "Clinical utility of 3% diquafosol ophthalmic solution in the treatment of dry eyes". Clinical Ophthalmology. 9: 865–872. doi:10.2147/OPTH.S69486. PMC 4440420. PMID 26028958.
- "FDA approves new medication for dry eye disease". FDA. July 12, 2016. Archived from the original on 13 July 2016. Retrieved 13 July 2016.
- "Restasis" (PDF). Allergan. January 2008. Archived (PDF) from the original on 2009-02-05. Retrieved 2008-07-23.
- Dantal J, Hourmant M, Cantarovich D, Giral M, Blancho G, Dreno B, Soulillou JP (1998). "Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens". The Lancet. 351 (9103): 623–28. doi:10.1016/S0140-6736(97)08496-1. PMID 9500317. S2CID 13063500.
60 patients developed cancers, 37 in the normal-dose group and 23 in the low-dose group (p<0.034); 66% were skin cancers (26 vs 17; p<0.05). The low-dose regimen was associated with fewer malignant disorders but more frequent rejection.
- "Sun Pharma Product List". Sun Pharma. Archived from the original on 2007-02-13. Retrieved 2006-11-27.
- Carter SR (June 1998). "Eyelid disorders: diagnosis and management". American Family Physician. 57 (11): 2695–702. PMID 9636333.
- Ervin, Ann-Margret; Law, Andrew; Pucker, Andrew D. (2017). "Punctal occlusion for dry eye syndrome". The Cochrane Database of Systematic Reviews. 6: CD006775. doi:10.1002/14651858.CD006775.pub3. ISSN 1469-493X. PMC 5568656. PMID 28649802.
- Qiao, J; Yan, X (2013). "Emerging treatment options for meibomian gland dysfunction". Clinical Ophthalmology. Auckland, N.Z. 7: 1797–803. doi:10.2147/OPTH.S33182. PMC 3772773. PMID 24043929.
- Gelatt, Kirk N. (June 2014). "Keratoconjunctivitis sicca | Nasolacrimal and Lacrimal Apparatus - Eye Diseases and Disorders". Merck Veterinary Manual. Retrieved 28 October 2020.
- Gelatt, Kirk N., ed. (1999). Veterinary Ophthalmology (3rd ed.). Lippincott, Williams & Wilkins. ISBN 978-0-683-30076-5.
- Guiliano, Elizabeth A. (2013). "Diseases and surgery of the canine lacrimal secretory system". In Gelatt, Kirk H. (ed.). Veterinary Ophthalmology (5th ed.). Ames, Iowa: Wiley-Blackwell. p. 919. ISBN 9780470960400.
- Stiles, Jean (2013). "Feline ophthalmology". In Kern, Thomas J. (ed.). Veterinary Ophthalmology (5th ed.). Ames, Iowa: Wiley-Blackwell. p. 1483. ISBN 9780470960400.
- Maskin, Steven L. (2007-05-28). Reversing Dry Eye Syndrome: Practical Ways to Improve Your Comfort, Vision, and Appearance. Yale University Press. ISBN 978-0-300-12285-5.
- Latkany, Robert (2007-04-03). The Dry Eye Remedy: The Complete Guide to Restoring the Health and Beauty of Your Eyes. Hatherleigh Press. ISBN 978-1-57826-242-7. Archived from the original on 2011-10-06.
- Patel, Sudi; Blades, Kenny (2003-04-10). The Dry Eye: A Practical Approach. Butterworth-Heinemann. ISBN 978-0-7506-4978-0. Archived from the original on 2011-06-07. Retrieved 2008-12-31.
- Geerling, Gerd; Brewitt, Horst (June 2008). Surgery for the Dry Eye: Scientific Evidence and Guidelines for the Clinical Management of Dry Eye Associated Ocular Surface Disease. S. Karger AG. ISBN 978-3-8055-8376-3.
- Penny Asbell; Lemp, Michael A. (November 2006). Dry Eye Disease: The Clinician's Guide to Diagnosis And Treatment. Thieme Medical Publishers. ISBN 978-1-58890-412-6. Archived from the original on 2009-09-24.
- Facts About the Cornea and Corneal Disease The National Eye Institute (NEI).
- Dry Eye Syndrome on NHS Choices
- Am.J.Managed Care - Dry Eye Disease: Pathophysiology, Classification, and Diagnosis
- Dry Eye Syndrome on eMedicine
- Nasolacrimal and Lacrimal Apparatus, The Merck Veterinary Manual